Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: mestranol, arzoxifene, synthetic conjugated estrogens, b +48 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 23 Parkinson's papers of 6,534 | 0.58 |
| pathways Reactome | 17 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 3211
Sealed predictions
- ESR1 in dopamine neurons, braak+0.47 (p 0.202) → +0.62 (p 0.074)receipt 3219
Swarm cases
receipt 3219: ESR1 in dopamine neurons, braak
- power
- full sample +0.55 (p 0.017, n 18), 95% CI +0.12 to +0.81. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.58 (p 0.012, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.51 (p 0.031, n 18). not the mix.
- skeptic
- leave-one-out range +0.49 to +0.73, sign flips 0; without severely affected donors +0.55 (p 0.017, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ESR1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts